Rx Compound 5
Rx Compound 5
Testosterone/DHEA/Progesterone Cream, 1 oz
This Three Hormone Cream is compounded with Testosterone, DHEA, Progesterone in a ratio of 3.6 : 20 : 5. Below is a breakdown of descriptions for each of these ingredients:
Testosterone is the primary androgen in the body that controls growth, development, and function of male sexual organs and characteristics. This is a controlled medication, commonly prescribed for the treatment of low testosterone levels in males (hypogonadism) who do not produce enough natural testosterone. It can also be prescribed in specific adolescent cases to induc epuberty in thosewho are experiencing a delay.
DHEA (Dehydroepiandrosterone) or 'the mother hormone' is secreted by the adrenal cortex and a steroid precursor of androgens and estrogens. This is commonly prescribed to help strengthen the immune system, promote weight loss, increase strength, and improve energy levels. It is also used for the treatment of lupus, multiple sclerosis, and Alzheimer disease.
Progesterone is a naturally occurring progestin; commonly prescribed in combination with estrogen-containing medications in postmenopausal women with a uterus to help reduce the risk of developing cancer of the uterus, as well as prevent abnormal thickening of the uterine lining in women taking estrogen. It is also used to regulate menstrual periods in women who are pre-menopausal but have stopped having periods due to low progesterone levels.
Recommended Usage:
Apply 1 gm externally for 1 month
This compound is dispensed upon Prescription Only.
USP General Chapter <795> Pharmaceutical Compounding – Nonsterile Preparations
Millions of medications are compounded each year in the US to meet the unique needs of patient, including vulnerable populations such as seniors and children. Compounding provides tailored therapy to patients who may not be able to use commercially available formulations due to dosing requirements, allergies or rare diseases.
Compounded drugs made without the guidance of standards may be sub-potent, super potent or contaminated, exposing patients to significant risk of adverse events or even death.
USP develops standards for compounding nonsterile drugs to help ensure patient benefit and reduce risks such as contamination, infection or incorrect dosing. USP General Chapter <795> provides standards for compounding quality nonsterile preparations. The chapter describes requirements for the compounding process, facilities, equipment, components, documentation, quality controls and training. General Chapter <795> also provides general guidelines for assigning beyond-use dates to nonsterile preparations.
Important Updates:
The General Chapter was last revised in its entirety in USP 34–NF 29, which became official on May 1, 2011. A Revision Bulletin was issued on Nov. 22, 2013, with an official date of Jan. 1, 2014, to clarify that the maximum beyond-use dates in the chapter may be applied only to nonsterile preparations.
A future revision to General Chapter <795> will be proposed in the Pharmacopeial Forum for public comment to harmonize with USP General Chapter <800>.
Important Dates
- TBD: Revision proposed in the Pharmacopeial Forum for public comment
While General Chapter <795> is undergoing revision, the published version of the chapter which became official on Jan 1, 2014 is currently official.
Developing USP General Chapter <795>
USP is a not-for-profit, science-driven organization that has an established process for convening independent experts for the development and maintenance of healthcare quality standards. The process is public health focused, leveraging current science and technology, and draws on the expertise of scientists and healthcare practitioners while providing opportunities for public input from stakeholders throughout the standard setting process.
The USP Compounding Expert Committee is responsible for the development of General Chapter <795>. Review their work plan and past meeting summaries. General Chapter <795> is currently under review and being considered for revision.